AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8871418
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effectiveness
Trial: 6207648
Drug: Ethambutol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethambutol (20 mg/kg bodyweight/day) with streptomycin and isoniazid (SHE)
Trial: 11863299
Drug: Formulation 1
RxNorm normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 1 (150 mg)
Trial: 11863299
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 2 (150 mg)
Trial: 25456363
Drug: Unfav-dose-dense group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfav-dose-dense group
Trial: 23064478
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections into the pectoralis major with or without injections to the teres major
Trial: 23064478
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections
Trial: 20103445
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for 168 days
Trial: 20103445
Drug: Traditional cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional cyclic regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for six 28-day cycles with a 7-day hormone-free interval
Trial: 15694572
Drug: Single course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single course of hylan G-F 20
Trial: 15694572
Drug: Repeat course
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat course of hylan G-F 20
Trial: 15694572
Drug: Appropriate care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate care without hylan G-F 20
Trial: 12706743
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of diethyl carbamazine citrate (DEC)
Trial: 12706743
Drug: 14 day
RxNorm normalized name: Ponvory 14 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day treatment with diethyl carbamazine citrate (DEC)
Trial: 10361567
Drug: Version M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Version M (mainstream drug - Metoprolol)
Trial: 10361567
Drug: Version V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Version V (unconventional drug - beef spleen cell extract)
Trial: 10150847
Drug: Nonsteroidal agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal agents
Trial: 1827622
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg orally for 6 days)
Trial: 1827622
Drug: Prednisolone (14.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (14.8 mg intravenously)
Trial: 7280443
Drug: Octavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octavalent vaccine (serotypes 1, 3, 6A, 7F, 14, 18C, 19F, and 23F)
Trial: 7280443
Drug: Heptavalent control
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent control vaccine (serotypes 2, 4, 5, 8, 9N, 12F, and 24F)
Trial: 7280443
Drug: Octavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octavalent vaccine
Trial: 7280443
Drug: Heptavalent control
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent control vaccine
Trial: 30912314
Drug: Lifebox LB-01
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifebox LB-01 probe with Masimo Rad-87 box (L + M)
Trial: 30912314
Drug: Lifebox LB-01
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifebox LB-01 probe and Lifebox V1.5 box (L + L)
Trial: 19117896
Drug: Separate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate vaccines (DTaP(5), IPV, Hib)
Trial: 9618132
Drug: Endoscopic pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic pancreatic therapy
Trial: 1895044
Drug: Enalapril (E),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (E), 20 mg d‐1
Trial: 1895044
Drug: Enalapril (E),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (E), 40 mg d‐1
Trial: 1895044
Drug: Slow-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release verapamil (V), 240 mg d‐1
Trial: 6200724
Drug: Intravenous isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isosorbide dinitrate infusion (50-200 micrograms/kg/h)
Trial: 6193353
Drug: Intravenous hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine (0.15 mg/kg)
Trial: 26280945
Drug: Flavonoid-rich orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-rich orange juice (240 ml, 272 mg flavonoids)
Trial: 24242903
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 µg bid
Trial: 24242903
Drug: Pasireotide 1,950
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 1,950 µg bid
Trial: 21060036
Drug: ULABTKA cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ULABTKA cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Trial: 21060036
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Trial: 21060036
Drug: ULABTKA cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ULABTKA cream
Trial: 9055051
Drug: Pediatric vaccine
RxNorm normalized name: hepatitis A pediatric vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric vaccine with lower protein content than adult vaccine; specific dosage not mentioned.
Trial: 9055051
Drug: Adult vaccine
RxNorm normalized name: hepatitis A adult vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult vaccine (approved); specific dosage not mentioned.
Trial: 8419809
Drug: Piracetam (2.4-16.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (2.4-16.8 g daily)
Trial: 3532292
Drug: Single nighttime
RxNorm normalized name: Flonase Nighttime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single nighttime dose of 800 mg cimetidine
Trial: 12205201
Drug: Interventional paired
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventional paired associative stimulation (IPAS) under the influence of dextromethorphan (an NMDA receptor antagonist).
Trial: 8916982
Drug: Immediate add-back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate add-back therapy (medrogestone 10 mg/day for 24 weeks)
Trial: 8916982
Drug: Deferred add-back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred add-back therapy (placebo for 12 weeks followed by medrogestone 10 mg/day for 12 weeks)
Trial: 1607464
Drug: Elastic compression
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic compression treatment
Trial: 6378211
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol (60 mg once a day)
Trial: 6378211
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol (20 mg three times a day)
Trial: 6378211
Drug: Long-acting propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol (60 mg once a day) after 8 days
Trial: 6378211
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol (20 mg three times a day) after 8 days
Trial: 22389082
Drug: 135 mg
RxNorm normalized name: cocaine 135 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg EGCG
Trial: 22389082
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including 135 mg EGCG and placebo)
Trial: 22389082
Drug: 270 mg
RxNorm normalized name: leucine 270 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mg EGCG
Trial: 17297526
Drug: Spirometry (pre-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirometry (pre- and post-bronchodilator)
Trial: 16140071
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of gemcitabine 2000 mg in 100 mL of unbuffered saline (n = 11)
Trial: 16140071
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 3 weeks (n = 11)
Trial: 16140071
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 6 weeks (n = 10)
Trial: 16140071
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with gemcitabine
Trial: 16140071
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects from gemcitabine treatment
Trial: 12040677
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg CGS20267 (Letrozole) once daily
Trial: 12040677
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg CGS20267 (Letrozole) once daily
Trial: 9462768
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine with hyaluronidase (15 U/cc)
Trial: 7541854
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor atamestane (400 mg daily for 48 weeks)
Trial: 60565
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of tobramycin and lincomycin
Trial: 28951372
Drug: Control (gargle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (gargle solution containing chlorhexidine gluconate)
Trial: 15958649
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E 1200 mg
Trial: 15958649
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (all doses)
Trial: 12653813
Drug: Lofexidine (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine (0.4, 0.8 and 1.6 mg, p.o.)
Trial: 12653813
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 and 0.2 mg, p.o.)
Trial: 12653813
Drug: Naloxone (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0, 0.1 and 0.3 mg, i.m.)
Trial: 7574011
Drug: Milrinone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (all doses combined)
Trial: 2038654
Drug: Eutectic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic mixture of local anaesthetics cream (EMLA) applied to the nasal vestibule
Trial: 25599968
Drug: Buprenorphine Transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine Transdermal System (BTDS) 10 and 20 mcg/hour
Trial: 25599968
Drug: Buprenorphine Transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine Transdermal System (BTDS) 20 mcg/hour
Trial: 25599968
Drug: Lower-dose control
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose control (BTDS 5 mcg/hour)
Trial: 23742734
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of written advance directive and proxy opinion
Trial: 15781537
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg standard morphine
Trial: 15781537
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg extended-release morphine (EREM)
Trial: 15781537
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg extended-release morphine (EREM)
Trial: 14723389
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anabolic-androgenic steroids)
Trial: 1914086
Drug: Mitozantrone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitozantrone and prednimustine (12 mg/m2 on day 1 and 130 mg/m2 orally on days 1-5, repeated every 4 weeks)
Trial: 6885201
Drug: 250‐mg naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250‐mg naproxen tablet I from AFI
Trial: 6885201
Drug: 250‐mg naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250‐mg naproxen tablet II Naprosyn
Trial: 31759769
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with relatively high fasting insulin (RHI)
Trial: 31759769
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with relatively low fasting insulin (RLI)
Trial: 29602570
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) therapy optimization
Trial: 29602570
Drug: Nonoptimized Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nonoptimized Adalimumab (ADA) therapy
Trial: 22709772
Drug: WEV+ (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEV+ (daily self-monitoring of body weight, step count, F/V intake, and 16 fl oz of water before each main meal)
Trial: 22709772
Drug: WEV (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEV (daily self-monitoring of body weight, step count, and F/V intake)
Trial: 20626054
Drug: Modulated middle-frequency
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modulated middle-frequency electrical stimulation treatment for 20 min twice a week for 12 consecutive weeks at the Zusanli (ST36) and Sanyinjiao (SP6) acupoints
Trial: 10707104
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg miltefosine/day for 28 days
Trial: 10707104
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg miltefosine/day for 28 days
Trial: 10707104
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg miltefosine/day for 28 days
Trial: 10707104
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg miltefosine/day for 7-17 days
Trial: 2285202
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg/kg)
Trial: 2285202
Drug: Prednisolone sodium
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone sodium metasulfobenzoate (Solupred) (1 mg/kg)
Trial: 30561087
Drug: Four monthly
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four monthly sessions panretinal photocoagulation (MS-PRP)
Trial: 26870678
Drug: Dragons blood
RxNorm normalized name: HOMOSALATE 30 mg in 1 mL / OCTINOXATE 60 mg in 1 mL / OXYBENZONE 30 mg in 1 mL TOPICAL CREAM [Dragons Blood SPF15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dragons blood cream
Trial: 12421024
Drug: 0.6 g
RxNorm normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g omega-3 fatty acids (Maxigard) twice daily
Trial: 9467537
Drug: Midodrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (5 mg orally, 30 min before breakfast)
Trial: 9467537
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of midodrine and octreotide
Trial: 23108628
Drug: Methylprednisolone (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40-80 mg)
Trial: 21646002
Drug: Postoperative infection
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative infection requiring antibiotics
Trial: 15173402
Drug: 0.75 g/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g/100 g free phytosterols in gerbil diet
Trial: 15173402
Drug: Phytosterol-enriched tortilla
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol-enriched tortilla chips providing 1.5 g/d
Trial: 15173402
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with tortilla chips providing 0 g/d phytosterols
Trial: 11420737
Drug: Gel padded
RxNorm normalized name: Medicated Pad
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel padded glove
Trial: 29649054
Drug: Textured insole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Textured insole with physical therapy for 6 weeks
Trial: 29649054
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy only for 6 weeks
Trial: 27987397
Drug: Prophylactic Amoxicillin‐Clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic Amoxicillin‐Clavulanic acid 1.2g every 8h
Trial: 27987397
Drug: Clinically-driven antibiotics
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically-driven antibiotics
Trial: 24167479
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (elevated BGC by approx. 1.5 mmol/l)
Trial: 12736280
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy with autologous stem-cell transplant
Trial: 12736280
Drug: Standard conventional-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conventional-dose combination chemotherapy
Trial: 10695838
Drug: Disulfiram during
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram during the first month of treatment
Trial: 10695838
Drug: Matching of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching of patients with the structure of treatment
Trial: 10695838
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of the motivation phase and active treatment phase
Trial: 1608318
Drug: Metoclopramide 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.15 mg/kg (iv)
Trial: 1608318
Drug: Ephedrine 0.5
RxNorm normalized name: Ephedrine 0.5% Nasal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.5 mg/kg (im)
Trial: 1608318
Drug: Ephedrine 1
RxNorm normalized name: ephedrine 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 1 mg/kg (im)
Trial: 26920611
Drug: β-blocker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker therapy (various types including carvedilol, metoprolol succinate, bisoprolol, atenolol, metoprolol tartrate)
Trial: 26920611
Drug: Patients discharged
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients discharged on 50% of target dose or greater
Trial: 25174952
Drug: Oral nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicorandil 20 mg once daily for 1 week before and 6 months after PCI
Trial: 20958143
Drug: Lidocaine solution
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine solution for inhalation (LSI; 40 mg twice daily; eFlow nebulizer)